Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference155 articles.
1. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.;M Arnold;Lancet Oncol.,2019
2. Pain in cancer survivors; filling in the gaps.;M Brown;Br J Anaesth.,2017
3. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.;F Mols;Support Care Cancer.,2014
4. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.;M Seretny;Pain.,2014
5. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.;G Gutiérrez-Gutiérrez;Clin Transl Oncol.,2010
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献